MAIA Biotechnology, Inc.
MAIAHealthcare|Biotechnology|US
$1.06
+0.02 (+1.92%)
DCF Value
$269.53
Tangible Book / Share
$0.34
Cash / Share
$0.45
About
MAIA Biotechnology, Inc. is a clinical-stage biotech firm dedicated to discovering, developing, and commercializing treatments for various cancers, with a primary focus on non-small cell lung cancer. The company's leading experimental compound, THIO, is an investigational drug candidate that utilizes a unique dual mechanism by targeting telomeres and stimulating an immune response. Established in 2018, the enterprise maintains its headquarters in Chicago, Illinois.
Stock Price
-3.6%(1Y)
1M
-7.8%
3M
-25.4%
6M
-19.7%
YTD
-30.7%
1Y
-7.8%
3Y
-49.0%
5Y
-76.2%
Pipeline Summary
58 total trials0
Phase 1
2
Phase 2
2
Phase 3
0
Phase 4
Completed: 24Recruiting: 9Unknown: 9Not Yet Recruiting: 12Active: 2By Invitation: 1Terminated: 1
Active Trials (11)
Exercise in Hereditary ATTR (ATTRv) Amyloidosis
NCT07033715Amyloidosis, Hereditary, Transthyretin-Related
N/ARecruiting
Enrollment: 42 participants
THIO and Cadonilimab in Resectable Hepatocellular Carcinoma
NCT07446257Resectable Hepatocellular Carcinoma
Early P1Recruiting
Enrollment: 60 participants
Etrasimod as Prevention of Pouchitis
NCT07486921Pouchitis
Phase 2Recruiting
Enrollment: 40 participants
Improving Response to Chemotherapy by Adding Physical Exercise in the Neoadjuvant Setting of Breast Cancer Patients
NCT05976815Breast Cancer
N/ARecruiting
Enrollment: 86 participants
The Most Demanding Match Periods: Should GPS Data be Normalized
NCT07321496Most Demanding Periods
Active
Enrollment: 50 participants
Key Facts
Market Cap$65.4M
Employees13 (+0% YoY)
CEOVlad Vitoc
IPO DateJul 28, 2022
Beta0.30
52-Week Range$0.87 – $3.19
Avg Volume478,549
ExchangeAMEX
WebsiteMAIABiotech.com
Ownership
Float131.6%
Shares Outstanding61.7M
Recent Insider Trades
Theagene Jean-ManasseAWARD
Sep 30, 202632,012 shares @ $1.18
Smith StanAWARD
Sep 30, 202638,871 shares @ $1.18
Luput CristianAWARD
Sep 30, 202633,536 shares @ $1.18
Louie Ngar YeeAWARD
Sep 30, 202639,634 shares @ $1.18
Guerrero RamiroAWARD
Sep 30, 202632,012 shares @ $1.18
Peers
Recent News
MAIA Biotechnology Achieves Patient Enrollment Milestones in Ongoing Phase 2 and Pivotal Phase 3 Clinical Trials in Non-Small Cell Lung Cancer
Oct 7, 2026 · globenewswire.com
Diamond Equity Research Releases Update Note on MAIA Biotechnology, Inc. (NYSE: MAIA)
Oct 1, 2026 · globenewswire.com
MAIA: Meta Taps MongoDB CEO to Lead New Enterprise AI Platform, ft. Seth Fiegerman | Open Interest
Sep 28, 2026 · youtube.com
MAIA Biotechnology Expands Pivotal Phase 3 THIO-104 Non-Small Cell Lung Cancer Trial into Spain and Portugal
Sep 23, 2026 · globenewswire.com
MAIA Biotechnology Reports Pivotal Phase 3 Clinical Trial Progress in Advanced Non-Small Cell Lung Cancer
Sep 22, 2026 · globenewswire.com
Data last updated: Nov 9, 2026, 04:20 AM